Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies

Thymoma (T) and thymic carcinoma (TC) are rare tumors of the mediastinum and optimal treatment regimens have not been elucidated. In part due to their rarity, much of our current data stem from retrospective analyses and there are few prospectively designed clinical trials to guide therapy.

Source: Lung Cancer - September 17, 2019 Category: Cancer & Oncology Authors: Jessica A. Hellyer, Matthew A. Gubens, Kristen M. Cunanan, Sukhmani K. Padda, Matthew Burns, A. John Spittler, Jonathan W. Riess, Melanie San Pedro-Salcedo, Kavitha J. Ramchandran, Joel W. Neal, Heather A. Wakelee, Patrick J. Loehrer Source Type: research